Quell Therapeutics is developing cell engineering that aims to treat autoimmune diseases

UK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn

One of the most promising UK biotech start-ups, Quell Therapeutics, has signed a research collaboration and licensing deal with AstraZeneca to develop treatments for two autoimmune diseases.
The pharma giant will pay Quell $85mn upfront and up to $2bn more if it meets various development and commercialisation milestones over the next few years.
This story originally appeared on: Financial Times - Author:Clive Cookson